Cobimetinib for Metastatic Melanoma
Overview
Overview
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Specific enhancer elements modulate phenotype plasticity and drug resistance in melanoma.
DeGeorgia S, Kaufman C bioRxiv. 2025; .
PMID: 39764051 PMC: 11702536. DOI: 10.1101/2024.12.12.628224.
Melanoma Cell Death Mechanisms.
Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong C Chonnam Med J. 2018; 54(3):135-142.
PMID: 30288368 PMC: 6165917. DOI: 10.4068/cmj.2018.54.3.135.
References
1.
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Daud A
. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014; 15(9):954-65.
DOI: 10.1016/S1470-2045(14)70301-8.
View
2.
Larkin J, Ascierto P, Dreno B, Atkinson V, Liszkay G, Maio M
. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20):1867-76.
DOI: 10.1056/NEJMoa1408868.
View
3.
Atkinson V
. Medical management of malignant melanoma. Aust Prescr. 2015; 38(3):74-8.
PMC: 4653963.
DOI: 10.18773/austprescr.2015.028.
View
4.
Ascierto P, McArthur G, Dreno B, Atkinson V, Liszkay G, Di Giacomo A
. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9):1248-60.
DOI: 10.1016/S1470-2045(16)30122-X.
View